Looking at IPXL's Global Division, IPX066 and its other product now in trials both address CNS conditions. Teva has recently announced a new strategy in which CNS is one of three focus sectors, and small to medium acquisitions will be growth drivers. Teva's CNS portfolio includes Azilect/Rasagiline, which Rytary could displace in some patients. The companies seem to know each other well - see recent CFO appointment. IPXL's revenue comes overwhelmingly from the generics division. Are branded products really a strategic priority for the company? Or could they be interested in selling them off (after FDA approval) to reinvest in generics? Not pumping - just curious if any one out there has an opinion.